MedTrace Logo

HF Patients With LVADs Being Treated With SGLT2i

NCT05278962 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2026-05-08

Study results available
· View outcomes & findings →

Summary

The main purpose of this study is to observe outcomes of sodium-glucose co-transporter 2 inhibitors (SGLT2i) in heart failure (HF) patients with left ventricular assist devices (LVAD).

Conditions

  • Heart Failure With Reduced Ejection Fraction

Interventions

DRUG

SGLT2i

empagliflozin (10 mg daily) or dapagliflozin (10 mg daily), depending on formulary coverage

OTHER

No SGLT2i

No SGLT2i

Sponsors & Collaborators

  • University of Chicago

    lead OTHER

Principal Investigators

  • Mark Belkin, MD · University of Chicago

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-09-08
Primary Completion
2025-08-31
Completion
2025-08-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05278962 on ClinicalTrials.gov